GTx Shares Up 26% On Enobosarm's Positive Results To Treat Urinary Incontinence

(RTTNews) - Shares of GTx Inc. (GTXI) is currently up 26% on the Nasdaq after the company Monday reported additional positive results from a phase 2 trial of its drug for postmenopausal women with stress urinary incontinence.

Memphis, Tennessee-based Gtx released additional results from a Phase 2 proof-of-concept clinical trial of 3 mg enobosarm administered orally in postmenopausal women with stress urinary incontinence, including magnetic resonance imaging results from patients' pelvic floor muscle.

The new data also suggests a positive treatment effect of enobosarm for urge incontinence suggesting a possible treatment effect for women with mixed incontinence.

Results from a pre-specified analysis of MRI data demonstrate a statistically significant increase in pelvic floor muscle thickness and urethral muscle diameter after enobosarm treatment. Treatment with enobosarm also reduced mean urge incontinence episodes by approximately 68 percent in patients who experienced urge incontinence as well as stress urge incontinence.

"Enobosarm's overall treatment effect was consistent with previously announced results, and importantly, these new results demonstrate that enobosarm may address a broader treatment need since many women suffer from symptoms of both stress and urge incontinence, also known as mixed incontinence," said Kenneth Peters, M.D., Chairman of Urology, Oakland University William Beaumont School of Medicine, and the principal investigator in the trial.

"In addition, with the MRI results, we are seeing anatomical changes supporting enobosarm's mechanism of action on pelvic floor muscle."